WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009139891) ANTAGONISTS OF BMP9, BMP10, ALK1 AND OTHER ALK1 LIGANDS, AND USES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/139891    International Application No.:    PCT/US2009/003016
Publication Date: 19.11.2009 International Filing Date: 15.05.2009
IPC:
C07K 16/18 (2006.01), A61P 35/00 (2006.01), A61P 37/00 (2006.01)
Applicants: ACCELERON PHARMA, INC. [US/US]; 149 Sidney Street Cambridge, MA 02139 (US) (For All Designated States Except US).
SEEHRA, Jasbir [US/US]; (US) (For US Only).
KNOPF, John [US/US]; (US) (For US Only).
PEARSALL, Robert, S. [US/US]; (US) (For US Only).
GRINBERG, Asya [RU/US]; (US) (For US Only).
KUMAR, Ravindra [US/US]; (US) (For US Only)
Inventors: SEEHRA, Jasbir; (US).
KNOPF, John; (US).
PEARSALL, Robert, S.; (US).
GRINBERG, Asya; (US).
KUMAR, Ravindra; (US)
Agent: EL-HAYEK, Roque; (US)
Priority Data:
61/053,644 15.05.2008 US
11/982,738 02.11.2007 US (IA Considered Withdrawn 13.07.2009)
Title (EN) ANTAGONISTS OF BMP9, BMP10, ALK1 AND OTHER ALK1 LIGANDS, AND USES THEREOF
(FR) ANTAGONISTES DE BMP9 ET BMP10, ALK1 ET AUTRES LIGANDS ALK1, ET LEURS UTILISATIONS
Abstract: front page image
(EN)In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of BMP9 and/or BMP10, ligands for ALK1, may also be used to inhibit angiogenesis in vivo.
(FR)Sous certains aspects, la présente invention est fondée sur l'idée qu'un polypeptide renfermant une partie de liaison à un ligand du domaine extracellulaire du polypeptide d'activine-like kinase I (ALK1) peut être utilisé pour inhiber l'angiogenèse in vivo, en particulier chez des mammifères souffrant de troubles se rapportant à l'angiogenèse. Sous certains aspects, l'invention démontre que des antagonistes de BMP9 et/ou BMP10 et des ligands pour ALK1 peuvent également être utilisés pour inhiber l'angiogenèse in vivo.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)